MyEloma Renal Impairment Trial: adjunctive plasma exchange in patients with newly diagnosed multiple myeloma and acute renal failure

Not Applicable

Completed

• Conditions: Myeloma; Cancer; Multiple myeloma and malignant plasma cell neoplasms

• Registration Number: ISRCTN37161699
• Lead Sponsor: Imperial College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2000-09-21
• Study Completion: 2008-12-31
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

Patients with newly diagnosed myeloma and acute renal failure, aged 18 years or over

Added as of 10/12/2009:
1. Newly diagnosed myeloma
2. Acute renal failure (creatinine greater than 500 mmol/l, urine output less than 400 ml/d or requiring dialysis)
3. Aged 18 years or over, either sex
4. Written informed consent
5. No previous chemotherapy for myeloma
6. No significant intrinsic renal disease unrelated to myeloma

Exclusion Criteria

Does not comply with above inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Added as of 10/12/2009:<br> Proportion of patients alive and dialysis-independent at 100 days.<br>

Secondary Outcome Measures

Name	Time	Method
<br> Added as of 10/12/2009:<br> 1. To determine whether addition of plasma exchange to chemotherapy affects overall survival<br> 2. To assess the impact of the addition of plasma exchange to chemotherapy on patients' quality of life<br> 3. To assess the value of renal histology in predicting recovery of renal function<br> 4. To assess the value of serum free light chain assay in determining response of the myeloma to chemotherapy and recovery of renal function in patients with renal failure<br>